{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:02:19Z","timestamp":1789758139261,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["81270365"],"award-info":[{"award-number":["81270365"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hubei Province Health and Family Planning Scientific Research Project","award":["WJ2018H0013"],"award-info":[{"award-number":["WJ2018H0013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12944-019-1069-5","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T12:02:15Z","timestamp":1559390535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia"],"prefix":"10.1186","volume":"18","author":[{"given":"Lei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedong","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,1]]},"reference":[{"issue":"1","key":"1069_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.molmed.2007.11.004","volume":"14","author":"CY Wang","year":"2008","unstructured":"Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37\u201344.","journal-title":"Trends Mol Med"},{"issue":"2","key":"1069_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.vph.2005.07.012","volume":"44","author":"G Schmitz","year":"2006","unstructured":"Schmitz G, Langmann T. Pharmacogenomics of cholesterol-lowering therapy. Vasc Pharmacol. 2006;44(2):75\u201389.","journal-title":"Vasc Pharmacol"},{"issue":"9","key":"1069_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.amjcard.2005.08.011","volume":"96","author":"K Kajinami","year":"2005","unstructured":"Kajinami K, Akao H, Polisecki E, et al. Pharmacogenomics of statin responsiveness. Am J Cardiol. 2005;96(9):65\u201370.","journal-title":"Am J Cardiol"},{"issue":"6","key":"1069_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.metabol.2004.12.020","volume":"54","author":"C Lahoz","year":"2005","unstructured":"Lahoz C, Pe\u00f1a R, Mostaza JM, et al. Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment. Metabolism. 2005;54(6):741\u20137.","journal-title":"Metabolism."},{"issue":"1","key":"1069_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cca.2008.07.032","volume":"398","author":"MA Willrich","year":"2008","unstructured":"Willrich MA, Hirata MH, Genvigir FD, et al. CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clin Chim Acta. 2008;398(1):15\u201320.","journal-title":"Clin Chim Acta"},{"issue":"3","key":"1069_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/03014460600594513","volume":"33","author":"PP Singh","year":"2006","unstructured":"Singh PP, Singh M, Mastana SS. APOE distribution in world populations with new data from India and the UK. Ann Hum Biol. 2006;33(3):279\u2013308.","journal-title":"Ann Hum Biol"},{"issue":"1","key":"1069_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.neuint.2009.09.016","volume":"56","author":"CN Ferreira","year":"2010","unstructured":"Ferreira CN, Carvalho MG, Fernandes AP, et al. Comparative study of apolipoprotein-E polymorphism and plasma lipid levels in dyslipidemic and asymptomatic subjects, and their implication in cardio\/cerebro-vascular disorders. Neurochem Int. 2010;56(1):177\u201382.","journal-title":"Neurochem Int"},{"issue":"4","key":"1069_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrd2005","volume":"5","author":"SM Grundy","year":"2006","unstructured":"Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov. 2006;5(4):295\u2013309.","journal-title":"Nat Rev Drug Discov"},{"key":"1069_CR9","first-page":"1439","volume":"28","author":"FA Yousuf","year":"2015","unstructured":"Yousuf FA, Review IMP. Apolipoprotein E (Apo E) gene polymorphism and coronary heart disease in Asian populations. Pak J Pharm Sci. 2015;28:1439\u201344.","journal-title":"Pak J Pharm Sci"},{"issue":"1","key":"1069_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1475-2840-11-36","volume":"11","author":"Rajesh Chaudhary","year":"2012","unstructured":"Chaudhary R. Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol 2012; 11(1): p. 36\u201336.","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"1069_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/jcla.20428","volume":"25","author":"S Fallah","year":"2011","unstructured":"Fallah S, Seifi M, Firoozrai M, et al. Effect of apolipoprotein E genotypes on incidence and development of coronary stenosis in Iranian patients with coronary artery disease. J Clin Lab Anal. 2011;25(1):43\u20136.","journal-title":"J Clin Lab Anal"},{"issue":"6","key":"1069_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.clinbiochem.2006.02.002","volume":"39","author":"H Kharrazi","year":"2006","unstructured":"Kharrazi H, Vaisi RA, Sabokroh AR, et al. Association between apolipoprotein E polymorphism and coronary artery disease in the Kermanshah population in Iran. Clin Biochem. 2006;39(6):613\u20136.","journal-title":"Clin Biochem"},{"issue":"1","key":"1069_CR13","first-page":"155","volume":"23","author":"HY Aydogan","year":"2009","unstructured":"Aydogan HY, Isbir S, Kurnaz O, et al. Associations of lipoprotein lipase S447X and apolipoprotein E genotypes with low-density lipoprotein subfractions in Turkish patients with coronary artery disease. Vivo. 2009;23(1):155\u201361.","journal-title":"Vivo."},{"issue":"5","key":"1069_CR14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1089\/dna.2011.1464","volume":"31","author":"H Yilmaz-Aydogan","year":"2012","unstructured":"Yilmaz-Aydogan H, Kucukhuseyin O, Kurnaz O, et al. Investigation of polymorphic variants of PPARD and APOE genes in Turkish coronary heart disease patients. DNA Cell Biol. 2012;31(5):867\u201375.","journal-title":"DNA Cell Biol"},{"issue":"2","key":"1069_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1152\/physiolgenomics.2000.4.2.101","volume":"4","author":"JM Hagberg","year":"2000","unstructured":"Hagberg JM, Wilund KR, Ferrell RE. APO E gene and gene-environment effects on plasma lipoprotein-lipid levels. Physiol Genomics. 2000;4(2):101\u20138.","journal-title":"Physiol Genomics"},{"issue":"1","key":"1069_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1476-511X-10-48","volume":"10","author":"Rui Baptista","year":"2011","unstructured":"Rui B, Rebelo M, Decqmota J, et al. Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy. Lipids Health Dis 2011; 10(1): p. 48\u201348.","journal-title":"Lipids in Health and Disease"},{"issue":"4","key":"1069_CR17","doi-asserted-by":"publisher","first-page":"7890","DOI":"10.3390\/ijms16047890","volume":"16","author":"J Lagos","year":"2015","unstructured":"Lagos J, Zambrano T, Rosales A, et al. APOE polymorphisms contribute to reduced atorvastatin response in Chilean Amerindian subjects. Int J Mol Sci. 2015;16(4):7890\u20139.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1069_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jacl.2012.02.005","volume":"6","author":"M Hu","year":"2012","unstructured":"Hu M, Mak VWL, Tomlinson B. Polymorphisms in apolipoprotein E and apolipoprotein A-V do not influence the lipid response to rosuvastatin but are associated with baseline lipid levels in Chinese patients with hyperlipidemia. J Clin Lipidol. 2012;6(6):585\u201392.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"1069_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13024-016-0069-4","volume":"11","author":"L Zhong","year":"2016","unstructured":"Zhong L, Xie Y-Z, Cao T-T, et al. A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism. Mol Neurodegener. 2016;11(1):2.","journal-title":"Mol Neurodegener"},{"issue":"2","key":"1069_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3892\/etm.2014.2097","volume":"9","author":"X-H Zhan","year":"2015","unstructured":"Zhan X-H, Zha G-C, Jiao J-W, et al. Rapid identification of apolipoprotein E genotypes by high-resolution melting analysis in Chinese Han and African fang populations. Exp Ther Med. 2015;9(2):469\u201375.","journal-title":"Exp Ther Med"},{"key":"1069_CR21","first-page":"75","volume-title":"Methods in Molecular Biology","author":"Chunlin He","year":"2014","unstructured":"He C, Holme J, and Anthony J. SNP genotyping: the KASP assay, in Crop Breeding: Methods and Protocols, D Fleury and R Whitford, Editors 2014, Springer New York: New York, NY. p. 75\u201386."},{"issue":"10","key":"1069_CR22","first-page":"827","volume":"44","author":"SP Zhao","year":"2016","unstructured":"Zhao SP. Key points and comments on the 2016 Chinese guideline for the management of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44(10):827\u20139.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"39","key":"1069_CR23","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, et al. 2016 ESC\/EAS guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999\u20133058.","journal-title":"Eur Heart J"},{"issue":"12","key":"1069_CR24","doi-asserted-by":"publisher","first-page":"22694","DOI":"10.3390\/ijms151222694","volume":"15","author":"C Peng","year":"2014","unstructured":"Peng C, Deng Q, Li Z, et al. Risk-association of DNMT1 gene polymorphisms with coronary artery disease in Chinese Han population. Int J Mol Sci. 2014;15(12):22694\u2013705.","journal-title":"Int J Mol Sci"},{"issue":"349","key":"1069_CR25","doi-asserted-by":"publisher","first-page":"g4356","DOI":"10.1136\/bmj.g4356","volume":"349","author":"S Rabar","year":"2014","unstructured":"Rabar S, Harker M, O\u2019Flynn N, et al. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. Bmj. 2014;349(349):g4356.","journal-title":"Bmj."},{"issue":"1","key":"1069_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1086\/321276","volume":"69","author":"MD Ritchie","year":"2001","unstructured":"Ritchie M D, Hahn L W, Roodi N, ., et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69(1): p. 138\u2013147.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"1069_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1017\/S0029665107005435","volume":"66","author":"AM Minihane","year":"2007","unstructured":"Minihane AM, Jofre-Monseny L, Olano-Martin E, et al. ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation. Proc Nutr Soc. 2007;66(2):183\u201397.","journal-title":"Proc Nutr Soc"},{"issue":"24","key":"1069_CR28","first-page":"204","volume":"24","author":"F Nabatchian","year":"2008","unstructured":"Nabatchian F, Khaghani S, Miri R, et al. Apolipoprotein E polymorphism, paraoxonase-1 activity and coronary artery disease: is there a link. Pak J Med Sci Q. 2008;24(24):204\u20138.","journal-title":"Pak J Med Sci Q"},{"issue":"2","key":"1069_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/0003-4819-141-2-200407200-00013","volume":"141","author":"Y Song","year":"2004","unstructured":"Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004;141(2):137\u201347.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1069_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1399-0004.2005.00510.x","volume":"68","author":"D Evans","year":"2005","unstructured":"Evans D, Seedorf U, Beil F. Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia. Clin Genet. 2005;68(4):369\u201372.","journal-title":"Clin Genet"},{"issue":"2","key":"1069_CR31","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jacc.2006.05.009","volume":"48","author":"JB Muhlestein","year":"2006","unstructured":"Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia : the DIACOR (diabetes and combined lipid therapy regimen) study. J Am Coll Cardiol. 2006;48(2):396\u2013401.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1069_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/tpj.2009.25","volume":"9","author":"E Zintzaras","year":"2009","unstructured":"Zintzaras E, Kitsios GD, Triposkiadis F, et al. APOE gene polymorphisms and response to statin therapy. Pharmacogenomics J. 2009;9(4):248\u201357.","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"1069_CR33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/clinchem\/40.1.24","volume":"40","author":"P Richard","year":"1994","unstructured":"Richard P, Thomas G, de Zulueta MP, et al. Common and rare genotypes of human apolipoprotein E determined by specific restriction profiles of polymerase chain reaction-amplified DNA. Clin Chem. 1994;40(1):24\u20139.","journal-title":"Clin Chem"},{"key":"1069_CR34","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1186\/s12864-015-2180-2","volume":"16","author":"BT Ertiro","year":"2015","unstructured":"Ertiro BT, Ogugo V, Worku M, et al. Comparison of Kompetitive allele specific PCR (KASP) and genotyping by sequencing (GBS) for quality control analysis in maize. BMC Genomics. 2015;16:908.","journal-title":"BMC Genomics"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-019-1069-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12944-019-1069-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-019-1069-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T23:08:35Z","timestamp":1590880115000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-019-1069-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1069"],"URL":"https:\/\/doi.org\/10.1186\/s12944-019-1069-5","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]},"assertion":[{"value":"29 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of Zhongnan Hospital approved this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants were informed of data sharing with their name and identity hidden per consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"129"}}